Related references
Note: Only part of the references are listed.
Article
Oncology
The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme
Karla V. Ballman et al.
NEURO-ONCOLOGY (2007)
Article
Mathematical & Computational Biology
A design of phase II cancer trials using total and complete response endpoints
Y Lu et al.
STATISTICS IN MEDICINE (2005)
Article
Oncology
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
WKA Yung et al.
BRITISH JOURNAL OF CANCER (2000)
Share Paper
